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Human papilloma virus (HPV), known to be an etiological agent for genital cancers, has been suggested also to be a possible
contributory agent for lung cancer. Alternatively, lung cancer, formerly considered to be solely a smoker’s disease, may now be
more appropriately categorised into never smoker’s and smoker’s lung cancer. Through this paper we attempt to bring forth the
currentknowledgeregardingmechanismsofHPVgainingaccessintothelungtissue,variousstrategiesinvolvedinHPV-associated
tumorigenesis in lung tissue.
1.Introduction
The World Health Organization (WHO) states lung cancer
to be the most common cause of cancer-related deaths
worldwide (1.3 million/year). The most important and
common cause of lung cancer is the long-term exposure to
tobacco smoke. Nevertheless, the global burden of 15% of
men and 53% of women with lung cancer, which is not
attributable to tobacco smoking, amounts up to 25% of all
lung cancer cases worldwide [1]. That would position lung
cancer in never smokers among the top ten of the causes of
cancer-related deaths worldwide. Suggested risk factors for
the disease in never smokers include environmental tobacco
smoke,radongas,cookingoilvapours,indoorcoalandwood
burning, asbestos, genetic factors, and viral agents.
Syrj¨ anen in 1979 ﬁrst suggested the possibility of human
papilloma virus (HPV) involvement in bronchial squamous
cell carcinoma [2]. Several studies after that, put together,
further suggest strongly a role for HPV as an aetiological
agent of lung cancer. Starting from the preliminary step of
HPV gaining access to the lung tissue, discrete molecular
and genetic changes have to occur for tumor initiation and
progression. However, studies on HPV and lung cancer are
very limited, of which epidemiological reports outnumber
molecular mechanisms. There are several questions to be
answered to get a complete picture of any possible mech-
anism for HPV-induced lung cancer. This paper tries to
summarize work carried out in this ﬁeld and dwells into
possible mechanisms of molecular pathogenesis of HPV-
induced lung cancer.
2.HPV andCarcinogenesis
Humanpapillomaviruses,belongingtothePapillomaviridae
family, are DNA viruses and are strictly host speciﬁc and
exquisitely tissue tropic, having a preference to infect cuta-
neous or internal mucosal surfaces. Nearly 200 subtypes of
HPV have been identiﬁed which are categorized as high risk
(HR) and low risk (LR) based on their oncogenic potential.
HPV infects the keratinocytes found in the basal layer of
the skin (stratum germinativum). Several investigations have
convincingly proved the presence of human papilloma virus
in the lesions of upper aerodigestive tract (UADT). We have
previously described the distribution of HPV types in oral
cancer [3] as well as in the larynx [4]. The process of HPV-
induced cell transformation is a combined manifestation of
several discrete cellular, genetic, and molecular alterations
accumulated in the mucosal tissue, termed “condemned
mucosa syndrome,” which later progresses onto invasive2 Journal of Oncology
cancer [5]. The viral proteins E6 and E7 contribute predom-
inantly to the process of carcinogenesis and further tumor
progression. These oncoproteins interact with critical cell
cycleregulatorstohampertheiractivityensuingderegulation
of the cell cycle machinery leading to uncontrolled cell
proliferation. The virally encoded E6 binds to a cellular
ubiquitin/protein ligase, E6-AP, and to p53 resulting in
ubiquitination of p53 leading to its proteolytic degradation
[6]. On the other hand, the E7 oncoprotein binds to the pRb
dissociating the transcription factor E2F from the pRb/E2F
complex, resulting in the transcriptional activation of several
genes which facilitate cell proliferation. Rb/E7 complex
formation is important for E7-induced cell transformation
[7].
3.HPVand the Lung
3.1. Why to Study HPV in relation to Lung Cancer? The
Epidemiology. Rogli´ c et al. in 1975 and Rubel and Reynolds
in 1979 provided ﬁrst evidence for involvement of HPV in
benign bronchial lesions, through the observations of koilo-
cytosis in sputum samples characteristic of HPV infections
[8, 9]. Syrj¨ anen described that the epithelial changes seen in
bronchial carcinoma closely resembled HPV-induced genital
lesions [2].
Klein et al., in 2008, have beautifully concised worldwide
epidemiological data available in the HPV incidence in
lung cancer [10]. The study suggests an incidence of 24.5%
of HPV-associated lung cancers. The distribution pattern
ranges from a prevalence of 15% in the American continent
and 17% in Europe to a mean incidence of 35.7% in Asia.
In majority of the studies, the high-risk subtypes of HPV
detected in the lung cancer tissues were 16, 18, 31, and 33,
and the most prevalent low-risk subtypes were HPV 6 and
11. The alarmingly high percentages of incidences reported
in Greece (69%), Taiwan (78.5%), and Japan (79%) suggest
HPV to be the second most important possible etiological
agent of lung cancer after cigarette smoking and advocate the
need for further research in this issue.
3.2. The Histological Fondness. The human respiratory tract
hasadivergenthistologyofthemucousliningwithcolumnar
epithelium throughout the respiratory tract and stratiﬁed
columnar epithelium covering the mucosa of the pharynx
and larynx. The resulting squamocolumnar junctions (SCJs)
canbecomparedtoasimilarjunctioninthecervixandcould
favour establishment of HPV infections. Lung cancer can
be histologically categorised, based on the biology, therapy,
andprognosisassmall-celllungcarcinoma(SCLC)andnon-
small-cell lung carcinoma (NSCLC). NSCLCs are further
classiﬁed into squamous cell carcinoma (SCC), adenocarci-
noma (ADC), and large-cell lung carcinoma (LCLC). Lung
cancer in never smokers when considered as a diﬀerent
disease is more frequent in the NSCLCs than in SCLCs [11].
3.3. Mode of Transmission. HPV cannot bind to the live
tissue, instead infects the epithelial tissue through the
exposedbasalkeratinocytesfollowingmicroabrasionsofskin
as would occur after a sexual intercourse. However, how
a well-protected organ like lung deeply positioned in the
thoracic cavity, where probability of acquiring abrasions and
thereby getting exposed to HPV, is not clear. Multiple sex
partners, oral-genital sex, and oral-anal sex could be some of
the factors favouring transmission of HPV to the oral cavity
andoropharyngealcancers.Prevalenceofoncogenicmucosal
HPV is higher in younger age oral cavity or oropharynx
cancer cases whose sexual practices are typically associated
with sexual transmission of the virus [12].
The study results from two diﬀerent cancer registries
in the United States, Connecticut, and the Surveillance,
Epidemiology, and End Results (SEER) program tumor
registries report evidence of shared etiological factors of
various second primary cancers following anal and cervical
cancer. There were 275 cases of lung or bronchial cancer
following cervical cancer recorded in these registries as
compared with 91.8 expected cases, a relative risk of 3.0
(95% conﬁdence interval 2.7–3.4) [13]. Studies conducted
by Hennig et al. found that 49% of bronchopulmonary
carcinomas were detected to be HPV DNA positive in the
women who had a clinical history of CIN III lesions [14].
HPV 16 and 18 E6 mRNA detected in the peripheral
blood of cervical cancer patients [15] suggests a possibility
that HPV infection in the lung tissue may originate in
the cervix and later infect lung via a hematogenous spread
(Figure 1)[ 16]. It has also been suggested that the presence
of circulating HPV 16/18 DNA may act as a risk marker
f o rl u n gc a n c e r[ 17]. Peripheral blood mononuclear cells
(PBMCs) can function as HPV carriers and might spread the
virus through blood. In all the samples tested positive, the
HPVgenomewasfoundtobeintheepisomalform,although
in a low copy number [18].
All these reports put together designate oncogenic HPV
DNA as a possible risk factor in developing second primary
cancers after HPV-related primary neoplasias. Whether or
notpersistentHPVinfectionorHPV-inducedcervicalcancer
is a prerequisite for the development of HPV-associated lung
cancer needs further investigation.
3.4. Entry of Virus into the Cells. The entry of HPV into
the cells in vitro is initiated by binding to a cell surface
receptor in contrast to the in vivo situation where the
basement membrane is a primary site of virus binding [19].
Widely distributed and evolutionary conserved cell surface
receptors, heparin sulphate, and stabilizing proteoglycans
(HSPGs) are presumed to be epithelial cell receptors for
HPV [20]. The existence of HSPGs on the cell surface,
[21]a sw e l la se x t r a c e l l u l a rm a t r i x[ 22] of lung ﬁbroblasts,
can make them suitable receptors for viral entry into lung
tissue (Figure 1). As ubiquitous members of extracellular
membrane (ECM) microenvironment and hence the cancer
stem cell niche, HSPGs are major factors responsible for
the microenvironment changes, involved in the tumor ini-
tiation, progression, and malignant conversion [23]. HSPG
functions as an attachment factor in HPV infection, and
the resulting interaction promotes essential conformational
changes in viral capsid, but HSPGs are obviously not the cellJournal of Oncology 3
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Figure 1: Viral entry and integration. The diagram shows the entry of viral DNA into the lung tissue either through the microabrasions in
t h em e m b ra n eo rt h r o u ght h eh a e m a t o g e n o u sr o u t ef r o mad i ﬀerent entry point as cervix or anus. Molecules such as HSPGs and α-integrins
serve as surface receptors for the viral attachment and entry. Viral DNA exists and episome and later on integrates into the host genome
losing an FHIT gene allele resulting in heterozygosity and subsequently upregulates the expression of proapoptotic protein Bcl-2.
surface receptors that arbitrate virion internalization and the
subsequent events in infection. The cell adhesion receptors
α6 integrins have close association with HSPGs as matrix
components, and act as secondary receptors for HPV after
its interaction with HSPG [19]. The drug surviving side
population cells from human lung tumor tissue express the
α6 integrin otherwise termed as very late antigen-6 (VLA-
6) [24]. The presence of CD49f receptors (another term
for α6 integrins) in the adult mouse lung stem cells have
also been demonstrated [25] all suggestive of the possible
involvement of lung cancer stem cells in the HPV entry
leading to infection and cancer. The integrins, heterodimeric
glycoproteins comprising of α and β subunits, are expressed
in a variety of cell types, primarily involved in cell-matrix
and cell-cell interactions, act as virus receptors, and aid
in initial binding and/or internalization of viruses into the
host tissue. Of the various α and β subunits known, α6,
β4, and β1 play a major role in the HPV binding and
internalization. The preferential expression of α6 subunit
with the β4 subunit forming the α6β4 complex expressed
exclusively in the stratiﬁed squamous epithelium [26], the
primary sites of HPV infection, makes α6β4-integrin the
key receptor for HPV binding and possibly accounts for the
predominance of HPV in squamous cell carcinoma than in
other histologic subtypes of lung cancer.
3.5. Presence of HPV DNA in the Lung Cancer Tissue:
Proof for a Causal Association. Although the presence of
oncogenic HPV in the lung tumor tissue has been reported
in several studies, the causal association of the HPV and
lung cancer needs to be authenticated with evidence. An
argument supporting the causative role of HPV in the
tumorigenesis of lung tissue is that HPV DNA is indeed
integrated into the host genome, which is the initial key
step in the tumor initiation [27]. Furthermore, the viral
oncoproteins E6 and E7 are in fact found to be expressed in
the lung tumors, down regulating tumor suppressor genes
such as p53 [28]. Taiwanese nonsmokers had signiﬁcantly
high prevalence of HPV16/18, suggesting HPV infection as
a possible etiological agent of lung cancer in nonsmokers.
Moreover, the nonsmoking females are more prone to HPV
positivity than their male counterparts. Also, compared to
the male smokers, the female nonsmokers are at a higher risk
of having HPV in their lung tumor tissue [16]. The reason
for this gender-based prevalence is yet unidentiﬁed. Though
afewstudiesreportedHPVabsenceinnonsmokerswithlung
cancer, this can be attributed to the technical variations in
theexperimentalconditionssuchasspeciﬁcityoftheprimers
andprobesused,disparityinthestudysubjects,andaboveall
the overall prevalence of HPV in the study population.
4.HPV -I nd uc edL ungT iss ueCar cinog e nesis:
Possible Mechanisms
The process of HPV-mediated carcinogenesis is the con-
sequence of an integrated process of defective apoptosis,
neovascularisation, and cellular immortality [3]. Once the
pathogen gains entry into its tissue of interest, it takes up
the cellular machinery, replicates its genome, evades cell
apoptosis, and initiates tumor formation. A few possible
moleculareventsmanifesteduponHPVinfectioninaddition
to the already reported ones in the HPV-induced lung tumor
tissue are summarised here.
4.1. FHIT LOH. Once inside the cells, HPV genome inte-
grates into the host genome. The fragile site FRA3B, adjacent
to the fragile histidine triad (FHIT) is a site of integration
of HPV genome. The FHIT gene located in chromosome
3p14.2 undergoesfrequentalleleloss ofheterogeneity(LOH)
or homozygous deletions in several cancers including lung4 Journal of Oncology
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Figure 2: E6-mediated survival signaling. The ﬁgure summarizes the diﬀerent survival signalling pathways activated by the viral protein E6.
While it activates the mitogenic signals in the Ras/Raf/Mek pathway, E6 blocks the p53 activation in turn inhibiting the action of p21, all
ultimately inducing cell survival. E6 also upregulates the expression of epidermal growth factor receptor (EGFR) and inhibits apoptosis by
the activation of an inhibitor-of-apoptosis protein (cIAP2) thereby obstructing apoptosis.
cancer. Upon integration of HPV to this site, allele loss can
occurtotheFHITgene(Figure1).Astudyconductedamong
HPV infected, nonsmoking, female lung cancer patients
fromTaiwansuggestedthattumorigenesismaybeinpartdue
to the increase in frequency of the FHIT LOH, reducing the
expression of FHIT [29].
4.2. Bcl-2 Up-Regulation. The status of HPV in the tissue
may determine expression level of the proapoptotic protein
Bcl-2, the levels of which being signiﬁcantly higher in
integrated HPV positive patients than those that were
negative or with episomal forms (Figure 1)[ 30].
4.3. Ras Gene Mutations. One of the most important
molecular changes documented in lung cancer progression
is activation of dominant oncogenes such as ras family genes.
Of various genes in the ras family, k-ras gene is found to have
pointmutationsincodon12,inmostofthelungcarcinomas.
Also, in 50% of HPV positive lung tumors, k-ras mutation
wasseentocoexist,constitutivelyactivatingtheRas/Raf/Mek
pathway (Figure 2). This suggests that HPV infection is not
suﬃcient by itself for malignant transformation but requires
cooperation of the activated ras gene [31].
4.4. Does the E6 and E7 Genes Have the Same Role and
Importance in Lung Cancer Pathogenesis as They Have in
Cervical Cancer?
4.4.1. E6-p53. The E6 protein has a well-recognised sig-
nature in pathogenesis of HPV-induced cervical and oral
cancer. E6 is the major viral protein which can activate two
independent pathways to prevent apoptosis-p53-dependent
andp53-independentpathway[32].RelationshipbetweenE6
and p53 has been conclusively shown in HPV-infected cells
[33]. E6 protein binds to the E6-AP, a host cell ubiquitin
ligase, and p53 tumor suppressor protein simultaneously
and induces accelerated proteosomal degradation of p53
(Figure 2)[ 6].
Kinoshita et al. in 1995 reported expression of E6 mRNA
in the HPV 18 DNA-positive lung tumor tissues [34]. In
this study, they also put forward the possibility of cellular
targets of HPV other than p53. HPV E6 proteins are
indeed expressed in lung tumor tissues, which are negatively
associated with the p53 expression. The corresponding
downregulation of mdm2 and p21 (Waf1/Sdi1/Cip1), which
are the downstream targets of p53, leads to the conclusion
that HPV E6 protein can inactivate the expression of p53 in
lung tumor tissues (Figure 2)[ 27]. The human Dead-box
RNA helicase (DDX3), which plays a role in regulation of
geneexpressionviaRNAmetabolism,transcription,splicing,
mRNA export, and translation, has been associated with
development of viral associated cancers. DDX3 transcription
is predominantly regulated by p53, and p21 transcription is
being synergistically suppressed by the alteration of the p53-
DDX3 pathway via E6, in lung tumors. Reduction of p21
make lung cancer patients vulnerable to tumor reversion and
thereby bring about poor relapse-free survival [35].
4.4.2. E6-cIAP. The viral oncoprotein E6 can also promote
carcinogenesis by upregulating expression of inhibitors of
antiapoptosis proteins (IAPs). Inhibitors of antiapopto-
sis proteins (IAPs) directly inhibit caspases to block cellJournal of Oncology 5
apoptosis. HPV E6 upregulates the expression of cIAP2
via epidermal growth factor receptor (EGFR)/phosphatidyl
inositol 3-kinase (PI3K)/AKT cascade. CREB, which is a
regulatory targeting molecule of AKT, and is phosphorylated
via the EGFR/PI3K/AKT pathway, which plays a crucial role
in the upregulation of cIAP2 by E6 protein (Figure 2). This
upregulation has been shown to confer resistance to cisplatin
in HPV 16/18 infected lung cancer [36].
4.4.3.E6-Bak. TheBcl-2homologousantagonist/killer(Bak)
protein is a proapoptotic member of the Bcl-2 gene family
which is involved in apoptosis. In the p53-independent
pathway, E6 protein binds the Bak protein and degrades it.
The proapoptotic eﬀect of Bak is a main target of HPV E6
protein. E6 from high-risk HPV subtypes (16,18) and low-
risk type (11) can bind to Bak, in vitro,a n dc a ns t i m u l a t e
its degradation, in vivo. Bak can associate with E6-associated
protein in the absence of E6 in contrast to p53, and the
subsequent inhibits the Bak-induced apoptosis through this
E6-AP-dependent process [37]. Though the status of Bak
expression in HPV-induced lung cancer is yet to be studied,
westronglysuspectthismechanismtobeactiveinpromoting
the tumorigenesis of lung tissue.
4.4.4. E7-pRb. The coexpression of E7 along with the E6
is indispensable for the increased oncogenic activity of the
HPV. The E7 protein of the high-risk HPV has a strong
aﬃnity to bind to pRb, abrogating the pRb signalling
pathway. Kinoshita et al. in 1995 reported the coexpression
of E7 mRNA along with E6 mRNA in the HPV 18 DNA-
positive lung tumor tissue [34]. The cell cycle regulatory
gene CDKN2A regulated by pRb is found to be altered in
the HPV associated tumors. Of the two proteins encoded by
CDKN2A, p16INK4a and p14ARF, the former prevents the cells
from S-phase entry by inhibiting CDK4/6-mediated phos-
phorylation of Rb and the p14ARF is a p53 stabilizer. p16INK4a
gene is epigenetically modiﬁed by CpG island promoter
hypermethylation, thus silencing it. HPV E7 inactivates the
pRb, releasing the histone deacetylases (HDAC) from the
E2F-Rb-HDAC complex to enhance p16INK4a hypermethyla-
tion through chromatin remodelling by HDAC (Figure 3).
Enzymes named DNA methyl transferases (DNMTs) mainly
of three types (DNMT1, DNMT3a, and DNMT3b) by their
complex interplay establish the cytosine methylation pat-
tern. The p16INK4a promoter hypermethylation was analysed
using methylation-speciﬁc PCR (MSP), the results of which
showed p16INK4a hypermethylation in 59.7% of smoking
males, 36.6% of nonsmoking males, and 60.3% of non-
smoking females lung tumors among Taiwanese population
[38]. p16INK4a hypermethylation frequency in nonsmoking
female lung tumors with HPV infection was as high as 70%
compared to those without HPV infection, which was as
low as 30% [38]. A statistically signiﬁcant correlation was
observed only in the nonsmoking female lung cancer cases
(P = 0.017), but not in male smoking or nonsmoking lung
tumors. Furthermore, reports from the same research group
demonstrated involvement of HPV infection in increased
expression of the DNMT3b (DNA methyl transferase),
to cause p16INK4a promoter hypermethylation among the
nonsmoking female lung tumor (Figure 3)[ 39].
4.5. Role of E5 Protein of HPV in the Transforming Activity.
The HPV E5 viral protein has been shown to have weak
transforming activity. Once the HPV genome is integrated
into the host genome, the E5 gene is frequently deleted,
and hence the E5 gene expression is terminated during the
progression of disease from the low grade to malignant
stage [40, 41]. So if at all E5 protein has an eﬀect on
the process of carcinogenesis, it has to act as an early-
stage protein, that is, before the HPV genome integration.
The key activity of HPV E5 seems to be the upregulation
of EGF receptors in a ligand-dependent manner. The E5
protein controls mitogenic signalling pathways by forming
complex with EGFR [42, 43]. This complex formation
enhances the activation by EGF [43]. HPV E5 exerts its
action by upregulation of the EGF receptor in a ligand-
dependent manner. The mechanism by which the HPV E5
does this appears to be due to (i) a decrease in the rate
of receptor degradation mediated by binding of E5 to the
16kDa subunit of the endosomal proton pump ATPase and
(ii) a net increase in the receptor phosphorylation without
decreased downregulation [44, 45]. E5 protein can also
activate MAP kinases via PKC (protein kinase C) and Ras-
mediated receptor tyrosine kinase (RTK) pathway. The E5
protein can activate the nuclear oncogenes, c-jun and jun-
B, through the activation protein-1 (AP-1) binding site [46].
Theactivityoftumor-suppressorgenep21(Waf1/Sdi1/Cip1)
is being repressed through the activation of c-jun by the
HPV E5 protein, which promotes cell proliferation [47].
Suppression of p21 gene by HPV E5 activates the CDK4-
cyclin D complexes, which in turn phosphorylates pRb and
inactivates pRb checkpoint control leading to uncontrolled
cell replication (Figure 4).
The fact that the EGFRs are often upregulated in the
lung tumor tissues highlights the possibility of the E5 protein
playing a role in the early stages of the transformation
process. On the contrary, Crusius et al. reported that
the HPV 16 E5 protein modulates the stress-dependent
activation of ERK1/2 and p38 MAP kinase activation in
human keratinocytes by an EGF-independent mechanism
[48]. No studies are reported yet, indicating the presence of
HPV E5 protein in the lung tumor tissues. Studies towards
this aspect would probably suggest new vaccine candidates
or therapeutic targets against HPV-induced lung cancer.
4.6. Does ER-EGFR Crosstalk Favour HPV Persistence Lead-
ing to Tumorigenesis? HPV-Induced Lung Cancer Is More
Prevalent in Females Than in Males. Estrogen contributes
to a large extent to the onset of HPV infection and tumor
progression [49]. Though the presence of estrogen receptors
(ERs) in human lung tissue has been controversial for
many years, it has been proved beyond doubt that some
forms of both ERα and ERβ are indeed present in normal
lung cells as well as in lung tumors, which are undeniably
functional, as evidenced by the estrogen-induced cell pro-
liferation in the lung in vitro as well as in vivo;a c t i v a t i o n6 Journal of Oncology
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Figure 4: Possible role of E5 protein in tumor initiation. This
ﬁgure condenses the multiple pathways that are suspected to be
activated by viral protein E5 leading to cell survival. The mitogenic
signaling downstream of Ras, epidermal growth factor receptor
(EGFR) and protein kinase C (PKC) are turned on by the E5
protein. Additionally, E5 can also activate the activator protein-1
(AP-1), which through c-jun may result in cell survival.
of transcription from estrogen response elements (ERE)
in lung cancer cells by estrogen and estrogen-stimulated
secretion of a growth factor thought to be involved in lung
tumorigenesis, collectively demonstrating that ERs play a
biological role in the lungs [50]. Aromatase, the enzyme
involvedincatalysingthebiosynthesisofestrogen,isinduced
in cervical carcinomas favouring the increased expression of
viral oncogenes E6 and E7 [51]. This is expressed in lung
tissue also which catalyses the local production of estrogen
from androgen and is suggested to be a predictive biomarker
for the prognosis of NSCLCs [52]. This enhanced local site
production of estrogen triggers the nongenomic mechanism
of estrogen action, which rapidly activates EGFR. The well-
establishedcrosstalkbetweenERandEGFRinheadandneck
cancers [53] arbitrates this action which is further validated
by the colocalised membrane ER and EGFR in the lung
tumors. Combined targeting of ER and EGFR in NSCLC
has been proved to enhance antiproliferative eﬀects in the
treatment of lung cancer [54]. We strongly argue that this
ER-EGFR crosstalk could occur in the lung tissue which
can consequently favour HPV persistence and malignant
transformation of the lung tissue (Figure 5). Furthermore,
when this probable crosstalk ﬁts in position, the increased
vulnerability of female never smokers to develop HPV-
induced lung cancer as well as the histologic aﬃnity of HPV
to NSCLC is better explained.
4.7. Estrogen—Hypoxia-Induced Factor—EGFR Crosstalk.
Hypoxia-inducible factors (HIFs) are heterodimeric tran-
scription factors that respond to changes in available oxygen
in the cellular environment, speciﬁcally, to decreases in
oxygen, or hypoxia by promoting the transcription of several
hypoxia inducible genes. HIFs are frequently upregulated
in solid tumors and are found to be expressed in three
isoforms—HIF-1, HIF-2, and HIF-3— each with an α andJournal of Oncology 7
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Figure 5: Possible estrogen-EGFR-HIF-1α crosstalk. Diagrammatic representation of the possible crosstalks between estrogen, epidermal
growth factor receptor (EGFR), and hypoxia-inducible factor-1α (HIF-1α) activating the mitogenic signalling resulting in the cell survival.
a β subunit. Estrogen can regulate the HIF-1α expression
through PI3K-Akt pathway (Figure 5)[ 55]. The oncogenic
protein E7 of HPV props up HIF-1α-dependent transcrip-
tion by blocking the interaction of HDACs with HIF-1α
in a manner dependent on the HDAC binding domain of
E7. The E6 protein primarily blocks the inhibitory eﬀects
of p53 on HIF-1 activity [56]. HIF-1 induces expression of
the genes essential for adapting to hypoxia including those
for erythropoietin, glucose transporters, glycolytic enzymes,
andvascularendothelialgrowthfactor(VEGF),elicitingsuc-
cessful homeostatic regulation under hypoxic conditions. In
cervical cancer, VEGF upregulates EGFR and downregulates
IGF-BP3, thus amplifying the cell proliferative activity of
EGFR (Figure 5). This action of VEGF seems to be mediated,
directly through EGFR or indirectly through HPV-E6 in the
HPV-positive cancers [57]. EGFR upregulation triggers the
downstreammitogenicsignalssupportingtumorigenesis.We
stronglysuspectthismechanismtobeactiveinHPV-infected
lung tissue which favours angiogenesis and metastasis.
5.TherapeuticStrategies
Would the vaccines such as Gardasil, Cervarix, and so
forth, directed towards the cervical cancer ensure protection
against HPV-induced lung cancer too? This would be a focal
question of interest that needs to be addressed to combat
the disease prophylactically. Given that the HPV subtypes
infecting and most of the molecular events occurring in
the cervical cancer may be extended to HPV-induced lung
cancer, these vaccines can presumed to be eﬀective against
lung cancer too.
Lung cancer in nonsmokers is molecularly diﬀerent
disease from that seen in the smoker population. Mutation
frequency as well as proﬁle of the genes encoding EGFR,
p53 and k-ras is conspicuously dissimilar in smoking and
nonsmoking groups. Also, the HPV infection paves way
to altering the signalling pathways leading to cancer. The
fact that EGFR has a crucial role in lung carcinogenesis
makes it an admirable target for therapy. Monoclonal
antibodies targeted against EGF receptors, small molecule
TK inhibitors, and antisense oligonucleotides can reduce
the activity of EGFR thereby inactivating the mitogenic
signalling pathways like Ras/Raf/Mek and PI3k/Akt/mTor
pathway. One such anti-EGFR monoclonal antibody being
used is cetuximab , in combination with chemotherapeutic
agents such as Carboplatin and Paclitaxel, when provided
concurrently or sequentially gave positive results in clinical
trials [58–60]. Other than these, matuzumab which is a
human monoclonal antibody, along with chemotherapy
and certain other multikinase inhibitors, can be used in
the treatment of advanced non-small-cell lung cancer [61].
Tyrosine kinase inhibitors such as Geﬁtinib interrupt the
downstream signalling activated during the binding of
ligands or mutational activation of EGFR [62]. Combined
targeting of estrogen receptor and EGFR, using fulvestrant
and geﬁtinib has proved to have enhanced antiproliferative
eﬀects in the in vivo studies [55]. Combination therapy
targeting HIFs and EGFR would probably also enhance the
treatment outcome.
MEK,amitogenicsignallingpathwayproteinactivatedas
a result of k-ras mutations in HPV infection is another, suit-
able target for therapy. Ci-1040 diﬂuorobenzamide is a MEK8 Journal of Oncology
inhibitor which has been clinically tested in NSCLC patients
[63]. Inhibitors of mammalian target of rapamycin (mTor),
a protein kinase which regulates cell growth by regulating
diﬀerent cell processes: Rapamycin and Temsirolimus, gave
partial response in patients with NSCLC [64].
6. Conclusion andFuturePerspectives
From the reported studies and suspected crosstalks, we
robustly argue EGFR to be a core molecular hub in patho-
genesis of HPV-induced lung cancer. It can be presumed that
combination therapy targeting EGFR and other molecules
having crosstalk with EGFR may be eﬀective in treatment
of the disease rather than a single target therapy. It is still
not apparent whether HPV is a causal factor of lung cancer
or whether it is just an opportunistic pathogen in the lung
cancer tissue and the exact molecular mechanisms behind
it. Almost all of the signalling pathways having a role in
lung cancer are found to be altered or blocked by human
papilloma viral proteins initiating tumorigenesis. Further
evidence is mandatory to substantiate beyond doubt the
causative role of HPV in the lung tissue tumorigenesis.
Moreover, the cofactors supplementing the HPV in the
transformation processes are yet to be classiﬁed. Studies
directed towards these targets would give a clearer image of
the disease which will eventually pave the way to designing
new prophylactic or therapeutic strategies in combating the
disease.
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